Leerink Partnrs Has Positive View of Envista FY2027 Earnings

Envista Holdings Co. (NYSE:NVST - Free Report) - Equities research analysts at Leerink Partnrs lifted their FY2027 earnings per share (EPS) estimates for shares of Envista in a research report issued on Wednesday, February 5th. Leerink Partnrs analyst M. Cherny now expects that the company will earn $1.45 per share for the year, up from their prior estimate of $1.41. Leerink Partnrs currently has a "Hold" rating on the stock. The consensus estimate for Envista's current full-year earnings is $1.06 per share.

Envista (NYSE:NVST - Get Free Report) last announced its earnings results on Wednesday, February 5th. The company reported $0.24 EPS for the quarter, topping analysts' consensus estimates of $0.23 by $0.01. Envista had a negative net margin of 44.56% and a positive return on equity of 3.86%.

NVST has been the topic of several other reports. Stifel Nicolaus upped their target price on Envista from $18.00 to $21.00 and gave the company a "buy" rating in a research report on Wednesday, October 23rd. Robert W. Baird increased their price objective on shares of Envista from $17.00 to $22.00 and gave the company a "neutral" rating in a research report on Thursday, October 31st. Morgan Stanley boosted their target price on shares of Envista from $19.00 to $20.00 and gave the stock an "equal weight" rating in a research report on Thursday, February 6th. Needham & Company LLC reaffirmed a "hold" rating on shares of Envista in a report on Thursday, February 6th. Finally, Piper Sandler upped their target price on Envista from $17.00 to $18.00 and gave the company a "neutral" rating in a research report on Monday, February 3rd. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and three have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $20.21.

Envista Stock Up 3.0 %

NYSE NVST traded up $0.63 on Monday, hitting $21.49. The stock had a trading volume of 1,992,297 shares, compared to its average volume of 2,225,396. Envista has a 52-week low of $15.15 and a 52-week high of $23.06. The business's fifty day moving average price is $19.90 and its 200 day moving average price is $19.28. The company has a debt-to-equity ratio of 0.44, a current ratio of 2.04 and a quick ratio of 1.77. The stock has a market cap of $3.70 billion, a price-to-earnings ratio of -3.31, a price-to-earnings-growth ratio of 2.06 and a beta of 1.34.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. purchased a new position in Envista during the third quarter worth about $31,000. GAMMA Investing LLC boosted its stake in Envista by 69.8% during the third quarter. GAMMA Investing LLC now owns 1,766 shares of the company's stock worth $35,000 after buying an additional 726 shares during the period. Huntington National Bank increased its position in shares of Envista by 97.8% during the third quarter. Huntington National Bank now owns 1,919 shares of the company's stock valued at $38,000 after acquiring an additional 949 shares during the last quarter. Venturi Wealth Management LLC raised its stake in shares of Envista by 528.4% in the 4th quarter. Venturi Wealth Management LLC now owns 1,948 shares of the company's stock valued at $38,000 after acquiring an additional 1,638 shares during the period. Finally, Blue Trust Inc. lifted its holdings in shares of Envista by 69.7% in the 3rd quarter. Blue Trust Inc. now owns 1,957 shares of the company's stock worth $39,000 after acquiring an additional 804 shares during the last quarter.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.